Searched for
LUPIN PHARMACEUTICAL NEWS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drugLupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement...
- Lupin shares in focus as USFDA inspection at Somerset facility concludes with no observationsEarlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 manufacturing facili...
- Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiaryLupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development ...
- Lupin gains on USFDA nod to market Sevelamer CarbonateAccording to data for September 2021 released by IQVIA MAT September, Sevelamer Carbonate for oral suspension had estimated annual sales of...
- Venus Remedies surges 13% on govt's PLI nodIn a release last month, the Ministry of Chemicals and Fertilisers said that 55 companies had qualified for the PLI scheme for the pharmace...
- Pharma stocks bleed as US states file lawsuit against generic drug firmsLupin, Aurobindo Pharma, Dr Reddy’s, Glenmark, Wockhardt USA and Zydus have been named in the lawsuit.
- Market Now: Nifty Pharma index top sectoral loser; Cadila, Glenmark Pharma decline over 2%Benchmark NSE Nifty50 index was 12 points up at 10,435, while the BSE Sensex was 36 points up at 33,610.
- Market Now: Nifty Pharma top sectoral gainer; Divi's Lab zooms over 16%Benchmark NSE Nifty50 index was 9 points up at 10,449, while the BSE Sensex was 55 points up at 33,656.
- Market Now: Nearly 90 stocks hit fresh 52-week low todayOnly Nifty Pharma and IT indices were trading in green.
- Lupin launches generic insomnia drug in USDrug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
- Be selective in pharma space; prefer Lupin, Cadila: Gaurav MehtaOnce a bit of sanity comes back to the market, people will start becoming a lot more stock-specific; Lupin is one name that stands out, say...
- Remain bullish on pharma sector: Deven Choksey'I remain bullish on pharmaceutical but would like to keep individual stocks in the watch list and buy them when the market gives opportuni...
- Lupin, Unichem Laboratories among global companies fined by European CommissionAs per the European Commission Anti-trust ruling, Lupin has been fined 40 million euros, while Unichem Laboratories 13.96 million euros.
- Lupin to market MSD's pneumonia prevention vaccine in IndiaAs part of the agreement promote and distribute MSD's 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in the cou...
- CLSA raises target price of Lupin, Cipla, Sun PharmaCLSA has increased target prices of pharmaceutical majors Lupin, Cipla and Sun Pharmaceuticals.
- Japan's Takeda eyes Lupin, Cipla pharma business; shares surge in morning tradeShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Cipla, Lupin shares surge in morning trade on boursesShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Lupin mulls sale of its Indian unit that markets drugsLupin Limited, the world's largest maker of drugs to fight tuberculosis, is considering selling its unit that markets drugs in India, said ...
- Lupin files second suit against RanbaxyMumbai-based drugmaker Lupin has filed a second suit in the US against Ranbaxy Laboratories to prevent the country’s largest drugmaker from...
Load More
